|

nal-IRI,5-fu,LV, benmelstobart, anlotinib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

  • Advanced Metastatic Pancreatic Cancer1
  • Cancer1

Other1 trial

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.